New Therapies Targeting apoB Metabolism for High-Risk Patients with Inherited Dyslipidaemias: What Can the Clinician Expect?
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
New Therapies Targeting apoB Metabolism for High-Risk Patients with Inherited Dyslipidaemias: What Can the Clinician Expect?
Authors
Keywords
Dyslipidaemia, Apolipoproteins, Cholesterol, Monoclonal antibody, Antisense oligonucleotide, Randomized controlled trial
Journal
CARDIOVASCULAR DRUGS AND THERAPY
Volume 27, Issue 6, Pages 559-567
Publisher
Springer Nature
Online
2013-08-02
DOI
10.1007/s10557-013-6479-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The safety of therapeutic monoclonal antibodies: Implications for cardiovascular disease and targeting the PCSK9 pathway
- (2013) A.L. Catapano et al. ATHEROSCLEROSIS
- Lipoprotein apheresis: State of the art and novelties
- (2013) C. Stefanutti et al. ATHEROSCLEROSIS SUPPLEMENTS
- The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular disease
- (2013) Gilbert R. Thompson ATHEROSCLEROSIS SUPPLEMENTS
- Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia
- (2012) Frederick Raal et al. CIRCULATION
- Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia
- (2012) Evan A. Stein et al. CIRCULATION
- Small dense LDL: An emerging risk factor for cardiovascular disease
- (2012) Satoshi Hirayama et al. CLINICA CHIMICA ACTA
- PCSK9, a novel target for lowering LDL cholesterol: promise and progress
- (2012) Hagai Tavori et al. Clinical Lipidology
- PCSK9 inhibition and LDL cholesterol lowering: the biology of an attractive therapeutic target and critical review of the latest clinical trials
- (2012) David Rhainds et al. Clinical Lipidology
- Highlighting the future potential of PCSK9-targeted therapeutics
- (2012) Michael Dowdall Clinical Lipidology
- Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial
- (2012) Maartje E. Visser et al. EUROPEAN HEART JOURNAL
- Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients
- (2012) David Sullivan et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The PCSK9 decade
- (2012) Gilles Lambert et al. JOURNAL OF LIPID RESEARCH
- Lipoprotein(a) as a Potential Causal Genetic Risk Factor of Cardiovascular Disease
- (2012) Sotirios Tsimikas et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels
- (2012) Clapton S. Dias et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy
- (2012) James M. McKenney et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study
- (2012) Michael J Koren et al. LANCET
- Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study
- (2012) Robert P Giugliano et al. LANCET
- Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial
- (2012) Evan A Stein et al. LANCET
- Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study
- (2012) Marina Cuchel et al. LANCET
- Lipoprotein(a) metabolism: Potential sites for therapeutic targets
- (2012) Jane Hoover-Plow et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
- (2012) Evan A. Stein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia
- (2012) Eli M. Roth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy
- (2012) Mary P. McGowan et al. PLoS One
- Accelerated subclinical coronary atherosclerosis in patients with familial hypercholesterolemia
- (2011) Lisan A. Neefjes et al. ATHEROSCLEROSIS
- ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
- (2011) et al. EUROPEAN HEART JOURNAL
- Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia
- (2011) Fatima Akdim et al. EUROPEAN HEART JOURNAL
- CT coronary plaque burden in asymptomatic patients with familial hypercholesterolaemia
- (2011) L. A. Neefjes et al. HEART
- Treatment of adults with Familial Hypercholesterolemia and evidence for treatment: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia
- (2011) Jennifer G. Robinson et al. Journal of Clinical Lipidology
- Optimal therapy for reduction of lipoprotein(a)
- (2011) G. Lippi et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol
- (2011) Judith Hsia et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Proprotein Convertases in Health and Disease
- (2011) Andrew W. Artenstein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Familial Hypercholesterolemia: The Lipids or the Genes?
- (2011) Akl C Fahed et al. Nutrition & Metabolism
- Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia
- (2010) Fatima Akdim et al. AMERICAN JOURNAL OF CARDIOLOGY
- Increased Secretion of Lipoproteins in Transgenic Mice Expressing Human D374Y PCSK9 Under Physiological Genetic Control
- (2010) Bronwen Herbert et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Lipoprotein(a) and ischemic heart disease—A causal association? A review
- (2010) Pia R. Kamstrup ATHEROSCLEROSIS
- Lipoprotein(a) as a cardiovascular risk factor: current status
- (2010) Børge G. Nordestgaard et al. EUROPEAN HEART JOURNAL
- Pharmacological Characterization of Diethyl-2-( acetyloxymethyl)-2-phenylmalonate (JTT-130), an Intestine-Specific Inhibitor of Microsomal Triglyceride Transfer Protein
- (2010) Y. Mera et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin Therapy
- (2010) Fatima Akdim et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
- (2010) Frederick J Raal et al. LANCET
- Statin Adverse Effects
- (2009) Beatrice A Golomb et al. American Journal of Cardiovascular Drugs
- Proprotein Convertase Subtilisin Kexin Type 9 Null Mice Are Protected From Postprandial Triglyceridemia
- (2009) Cédric Le May et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality
- (2009) JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia
- (2009) Maartje E. Visser et al. JOURNAL OF LIPID RESEARCH
- Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment
- (2008) John J.P. Kastelein et al. CIRCULATION
- Lack of Pharmacokinetic Interaction of Mipomersen Sodium (ISIS 301012), a 2′-O-Methoxyethyl Modified Antisense Oligonucleotide Targeting Apolipoprotein B-100 Messenger RNA, with Simvastatin and Ezetimibe
- (2008) Rosie Z Yu et al. CLINICAL PHARMACOKINETICS
- New approaches to target microsomal triglyceride transfer protein
- (2008) Mohammed Mahmood Hussain et al. CURRENT OPINION IN LIPIDOLOGY
- The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients
- (2008) Jean-Charles Fruchart et al. Diabetes & Vascular Disease Research
- Abetalipoproteinemia: two case reports and literature review
- (2008) Rola Zamel et al. Orphanet Journal of Rare Diseases
- Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia
- (2008) Frederick F Samaha et al. Nature clinical practice. Cardiovascular medicine
- A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias
- (2008) Jacqueline de Graaf et al. Nature clinical practice. Endocrinology & metabolism
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now